Cargando…

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Detalles Bibliográficos
Autores principales:	Masri, Ahmad, Olivotto, Iacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Viewpoints
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238628/ https://www.ncbi.nlm.nih.gov/pubmed/35502770 http://dx.doi.org/10.1161/JAHA.121.024656

Ejemplares similares

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy
por: Jacques, Adam M., et al.
Publicado: (2008)

Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
por: Maron, Barry J., et al.
Publicado: (2022)

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Addressing Medicine’s Dark Matter
por: Rose, Christian, et al.
Publicado: (2022)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Mitochondrial Energetics and Ca(2+)-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2020)

Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy
por: Arévalos, Victor, et al.
Publicado: (2021)

Histopathology of the Mitral Valve Residual Leaflet in Obstructive Hypertrophic Cardiomyopathy
por: Troy, Aaron L., et al.
Publicado: (2023)

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Moderating the Myosin Motor to Treat Hypertrophic Cardiomyopathy
por: Papp, Zoltán
Publicado: (2022)

Cardiac pacing in patients with hypertrophic obstructive cardiomyopathy
por: Tolosana, José Maria, et al.
Publicado: (2018)

Late sodium current inhibitors to treat exercise‐induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium
por: Ferrantini, Cecilia, et al.
Publicado: (2018)

Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Maurizi, Niccolò, et al.
Publicado: (2023)

Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy
por: Caniato, Flavia, et al.
Publicado: (2021)

Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy
por: Pelliccia, F., et al.
Publicado: (2021)

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy
por: Sherrid, Mark V., et al.
Publicado: (2021)

Hypertrophic Obstructive Cardiomyopathy
por: Cohen, Lawrence S.
Publicado: (1972)

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
por: Toepfer, Christopher N., et al.
Publicado: (2020)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2021)

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy
por: Kawana, Masataka, et al.
Publicado: (2017)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
por: Palandri, Chiara, et al.
Publicado: (2022)

The Hypertrophic Cardiomyopathy Myosin Mutation R453C Alters ATP Binding and Hydrolysis of Human Cardiac β-Myosin
por: Bloemink, Marieke, et al.
Publicado: (2014)

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy
por: El-Hamamsy, Ismail, et al.
Publicado: (2012)

Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner
por: Singh, Rohit R., et al.
Publicado: (2021)

β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity
por: Adhikari, Arjun S., et al.
Publicado: (2019)

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
por: Robert-Paganin, Julien, et al.
Publicado: (2018)

ECHOCARDIOGRAPHY FOR HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
por: Irpachi, Kalpna, et al.
Publicado: (2017)

Cardiac Catheterization in a Patient with Obstructive Hypertrophic Cardiomyopathy and Syncope
por: Nunes, Rafael Amorim Belo, et al.
Publicado: (2017)

Alternative Management Options for Hypertrophic Cardiomyopathy: Feasible?
por: Raimondo, Cristina, et al.
Publicado: (2020)

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy
por: Finocchiaro, Gherardo, et al.
Publicado: (2017)

Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study
por: Coppini, Raffaele, et al.
Publicado: (2019)

Unexpectedly Low Mutation Rates in Beta-Myosin Heavy Chain and Cardiac Myosin Binding Protein Genes in Italian Patients With Hypertrophic Cardiomyopathy
por: Roncarati, Roberta, et al.
Publicado: (2011)

Prevalence of cardiac myosin-binding protein C3 mutations in Maine Coon cats with hypertrophic cardiomyopathy
por: Sukumolanan, Pratch, et al.
Publicado: (2022)

Structural basis of the super- and hyper-relaxed states of myosin II
por: Craig, Roger, et al.
Publicado: (2021)

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy
por: Altibi, Ahmed M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bs85shk5lql1c5p26j5tnj9s5s